Because male HIV-positive people treated with HAART are living longer, the higher the possibility that they develop cancer, prostate cancer, for example. Target of this study published in the British Journal of Urology 2 April 2008 edition of the internet version is to determine the clinical characteristics and pathological findings and outcome of HIV-positive patients who were diagnosed and treated for prostate cancer.
Researchers at Baystate Hospital, Tufts University School of Medicine, Springfield, MA, USA conducted a retrospective study, involving a variety of the central male HIV-positive individuals with prostate cancer.
The researchers collected data on patient demographics (age, race / ethnicity), HIV status (CD4 count, HIV viral load, HAART), the level of prostate antigen (PSA) when diagnosed with cancer, signs and symptoms, radiological findings, pathology (Gleason score , stage), cancer treatment (type, side effects), and the results (response, survival), the data were analyzed using statistical picture.
Result
0 comments:
Post a Comment